company background image
ZYNE

Zynerba Pharmaceuticals NasdaqGM:ZYNE Stock Report

Last Price

US$0.61

Market Cap

US$27.4m

7D

-9.0%

1Y

-77.9%

Updated

07 Feb, 2023

Data

Company Financials +

Zynerba Pharmaceuticals, Inc.

NasdaqGM:ZYNE Stock Report

Mkt Cap: US$27.4m

ZYNE Stock Overview

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

ZYNE fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Zynerba Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zynerba Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.61
52 Week HighUS$2.94
52 Week LowUS$0.49
Beta1.72
1 Month Change12.55%
3 Month Change-6.48%
1 Year Change-77.90%
3 Year Change-87.87%
5 Year Change-94.66%
Change since IPO-96.25%

Recent News & Updates

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23
Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Shareholder Returns

ZYNEUS PharmaceuticalsUS Market
7D-9.0%-0.7%0.9%
1Y-77.9%4.9%-10.9%

Return vs Industry: ZYNE underperformed the US Pharmaceuticals industry which returned 4.9% over the past year.

Return vs Market: ZYNE underperformed the US Market which returned -10.9% over the past year.

Price Volatility

Is ZYNE's price volatile compared to industry and market?
ZYNE volatility
ZYNE Average Weekly Movement11.1%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ZYNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ZYNE's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200728Armando Anidohttps://www.zynerba.com

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.

Zynerba Pharmaceuticals, Inc. Fundamentals Summary

How do Zynerba Pharmaceuticals's earnings and revenue compare to its market cap?
ZYNE fundamental statistics
Market CapUS$27.42m
Earnings (TTM)-US$35.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZYNE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$35.83m
Earnings-US$35.83m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.80
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ZYNE perform over the long term?

See historical performance and comparison